Q4 2019 Biotec Pharmacon ASA Earnings Call Transcript
Okay. Welcome to the Q4 presentation. I'm Jethro Holter, the interim CEO, and I'm joined here today by Børge Sørvoll, who is our CFO. And Børge will share the presentation with me today. Just having a problem with the slides here. There we go. Now it's working.
So the agenda today is what I want to do is we're going to start off recapping the new strategic direction. This is what we presented at the Investor Update Meeting on 10th of December. We will then look at the highlights. We will look at the Q4 achievements and then what we delivered in 2019. We'll then look at the ArcticZymes business, Biotec BetaGlucans. Børge will then take you through the Q4 financials, and then we'll look at the outlook to see what to expect for 2020.
So in terms of the strategy, the new strategic direction, as mentioned, we had an Investors Update Meeting on the 10th of December, and we sort of outlined where we're going to go in the future. I'm going to touch base on the key aspects of that meeting.
For the company, we have one goal moving
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
